ADICET BIO INC's ticker is ACET and the CUSIP is 007002108. A total of 78 filers reported holding ADICET BIO INC in Q4 2023. The put-call ratio across all filers is 10.24 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $42,885 | +519.6% | 35,442 | +1103.5% | 0.00% | – |
| Q1 2024 | $6,921 | -69.8% | 2,945 | -75.7% | 0.00% | – |
| Q4 2023 | $22,899 | +53.3% | 12,116 | +11.1% | 0.00% | – |
| Q3 2023 | $14,941 | -45.6% | 10,906 | -3.6% | 0.00% | -100.0% |
| Q2 2023 | $27,488 | +161594.1% | 11,312 | +287.5% | 0.00% | 0.0% |
| Q1 2023 | $17 | +30.8% | 2,919 | +114.6% | 0.00% | 0.0% |
| Q4 2022 | $13 | -100.0% | 1,360 | -28.3% | 0.00% | – |
| Q3 2022 | $27,000 | +28.6% | 1,897 | +32.3% | 0.00% | – |
| Q2 2022 | $21,000 | -85.8% | 1,434 | -80.7% | 0.00% | -100.0% |
| Q1 2022 | $148,000 | +469.2% | 7,427 | +397.1% | 0.00% | – |
| Q4 2021 | $26,000 | +188.9% | 1,494 | +29.0% | 0.00% | – |
| Q3 2021 | $9,000 | -67.9% | 1,158 | -57.6% | 0.00% | -100.0% |
| Q2 2021 | $28,000 | -12.5% | 2,733 | +10.3% | 0.00% | 0.0% |
| Q1 2021 | $32,000 | +190.9% | 2,477 | +231.1% | 0.00% | – |
| Q4 2020 | $11,000 | -60.7% | 748 | -67.7% | 0.00% | – |
| Q3 2020 | $28,000 | – | 2,318 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Abingworth LLP | 2,115,385 | $42,160,000 | 11.96% |
| Foresite Capital Management V, LLC | 680,000 | $13,580,000 | 5.55% |
| Foresite Capital Opportunity Management V, LLC | 170,000 | $3,395,000 | 4.75% |
| Tri Locum Partners LP | 523,256 | $10,449,000 | 4.08% |
| DAFNA Capital Management LLC | 715,872 | $14,296,000 | 3.72% |
| Decheng Capital Management III (Cayman), LLC | 580,000 | $11,583,000 | 3.55% |
| COWEN AND COMPANY, LLC | 1,500,055 | $29,956,000 | 2.88% |
| JOHNSON & JOHNSON | 728,944 | $14,557,000 | 2.75% |
| Orbimed Advisors | 7,447,141 | $148,719,000 | 2.41% |
| Ikarian Capital, LLC | 507,348 | $10,132,000 | 1.33% |